A61K 47/6813
The drug being a peptidic cytokine
Official title: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
A61K47/6813 (The drug being a peptidic cytokine) appears on 365 US grants and 661 published applications in this corpus.
Search patents in A61K- Granted patents
- 365
- Published applications
- 661
- Assignees
- 266
- Inventors
- 1,001
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 4 |
| 2002 | 4 | 4 |
| 2003 | 3 | 28 |
| 2004 | 3 | 12 |
| 2005 | 2 | 9 |
| 2006 | 6 | 18 |
| 2007 | 1 | 14 |
| 2008 | 7 | 9 |
| 2009 | 10 | 18 |
| 2010 | 9 | 17 |
| 2011 | 9 | 22 |
| 2012 | 14 | 21 |
| 2013 | 14 | 22 |
| 2014 | 11 | 34 |
| 2015 | 26 | 29 |
| 2016 | 25 | 36 |
| 2017 | 24 | 36 |
| 2018 | 34 | 44 |
| 2019 | 23 | 36 |
| 2020 | 15 | 24 |
| 2021 | 25 | 21 |
| 2022 | 19 | 36 |
| 2023 | 13 | 56 |
| 2024 | 19 | 39 |
| 2025 | 15 | 31 |
| 2026 | 11 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Processes for preparing conjugates of the IL-2 protein1 Sep 2026US 12,723,058 B2Merck Sharp & Dohme Corp.
- Monoclonal antibody-cytokine fusion protein dimer and application thereof1 Sep 2026US 12,723,080 B2Nanjing GenScript Biotech Co., Ltd.
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- Combination therapy for treating cancer25 Aug 2026US 12,714,759 B2City of Hope
- Antibodies against human and canine IL-13RA225 Aug 2026US 12,715,926 B2Wake Forest University Health Sciences
- Antibody targeting dll3 and use of antibody8 Oct 2026US 2026/0308240 A1Neukio Biotherapeutics (Shanghai) Co., Ltd.
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
- Immunoconjugates containing tnf-alpha and related methods and compositions thereof24 Sep 2026US 2026/0284216 A1Suzhou Fuse Biosciences Limited
- Anti-tslp nanobodies and their applications17 Sep 2026US 2026/0274941 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Synthekine Compositions and Methods of Use10 Sep 2026US 2026/0263562 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008
- Multiple cytokine protein complexes145US 6,617,135 B1EMD Lexigen Research Center Corp. · 2003
- Immunotherapy of autoimmune disorders using antibodies which target B-cells140US 7,074,403 B1Immunomedics, Inc. · 2006
- Methods for chemically synthesizing immunoglobulin chimeric proteins119US 7,381,408 B2Syntonix Pharmaceuticals, Inc. · 2008
- Recombinant antibody cytokine fusion proteins116US 5,650,150 A1997